DENTSPLY SIRONA (NASDAQ: XRAY) and Integra Lifesciences (NASDAQ:IART) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Institutional & Insider Ownership
96.1% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 87.6% of Integra Lifesciences shares are owned by institutional investors. 2.0% of DENTSPLY SIRONA shares are owned by insiders. Comparatively, 21.5% of Integra Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a summary of recent ratings for DENTSPLY SIRONA and Integra Lifesciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DENTSPLY SIRONA presently has a consensus target price of $69.82, suggesting a potential upside of 6.12%. Integra Lifesciences has a consensus target price of $51.88, suggesting a potential upside of 2.58%. Given DENTSPLY SIRONA’s stronger consensus rating and higher probable upside, research analysts plainly believe DENTSPLY SIRONA is more favorable than Integra Lifesciences.
Volatility and Risk
DENTSPLY SIRONA has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Integra Lifesciences has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.5%. Integra Lifesciences does not pay a dividend. DENTSPLY SIRONA pays out -10.1% of its earnings in the form of a dividend.
Earnings & Valuation
This table compares DENTSPLY SIRONA and Integra Lifesciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DENTSPLY SIRONA||$3.75 billion||4.03||$429.90 million||($3.47)||-18.96|
|Integra Lifesciences||$992.08 million||4.00||$74.56 million||$0.61||82.90|
DENTSPLY SIRONA has higher revenue and earnings than Integra Lifesciences. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Integra Lifesciences, indicating that it is currently the more affordable of the two stocks.
This table compares DENTSPLY SIRONA and Integra Lifesciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
DENTSPLY SIRONA beats Integra Lifesciences on 10 of the 16 factors compared between the two stocks.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.